It was found that the Tapinarof cream improves the severity of atopic dermatitis in patients aged 2 years. This is based on the results of the 2 -year study in phase 3.
Tapinarof is an aryl hydrocarbon receptor agonist that is currently marketed under the brand name Vtama® For topical treatment of plaque psoriasis in adults.
The Adoring 2 -Study (Clinicalaltrials.gov Identifier: NCT05032859) included pediatric and adult patients with atopic dermatitis who were available for at least 6 months from 6 years or older or 3 months for two to 5 years. Study participants (n = 406) were randomly assigned to 2: 1 to be treated once a day with Tapinarof cream, 1% or vehicle cream.
The primary endpoint of the study was the proportion of patients who achieved a validated researcher of global evaluation for atopic dermatitis (Viga-Ad) with a clear (0) or almost clear (1) with a minimal improvement of the 2-degree basis up to the week 8 to week.
The results showed a significantly higher proportion of the patients treated with Tapinarof cream compared to patients who received the vehicle (46.4% compared to 18.0%; P <.0001). In addition, 59.1% of the patients treated with tapinarof recorded the improvement of the eczema surface and the severity of the severity (EASI) from baseline 8 compared to 21.2% of the vehicle arm (secondary end point; P <.0001).
Among the patients from the age of 12 with a basic line-peak pruritus numerality scale (PP-NRS) of 4 or more, 52.8% reached a 4-point reduction or a higher reduction in PP no. 24 VS 24.1% of the patients treated with vehicle (secondary end point; P = .0015).
“We are considerably encouraged by the positive results of Adoring 2, which indicates that VTAMA cream can be a potentially important non -steroidal, topical treatment option for patients in atopic dermatitis, including children at the age of 2, where we know that there is a convincing need,” said Philip M. Brown, MD, Chief Medical Officer at Dermavant. “We are now expecting very important data from TopLine data from our identically designed veneration 1 -attempt in May 2023.”
reference
Dermavant reports positive topline results from the veneration of 2 atopic dermatitis phase 3 study with Vtama® (Tapinarof) cream, 1% once a day in adults and children aged 2 years. Press release. Dermavant. March 15, 2023. IC-Dermatitis-Phase-3-Trial-of-Vtama%C2%AE-Tapinarof-CREAM-1-Once-in-Eerwaxene-and-Kinder-AS-2-year-old.
This article originally appeared on MPR